Pamatolol is a beta-Adrenergic receptor antagonist was studied as an Antiarrhythmic agent. The phase I clinical trial has shown that the drug was relatively cardioselective in man. Information about the further development of this drug is not available.

Lometrexol, formerly known as DDATHF; LY 264618; T-64 was the first glycinamide ribonucleotide formyl transferase (GARFT) inhibitor to be investigated clinically. Lometrexol had been in phase II clinical trial for the treatment non-small cell lung cancer (NSCLC). However, the studies have been discontinued by Tularik Inc, because Company had suggested, that drug would face competition from other companies in the indication

Menabitan is a synthetic cannabinoid exerting analgesic activity.

Iozomic Acid is triiodobenzoic acid derivative patented by Pharmacia Aktiebolag as X-ray contrast agent for Coronary Angiography.

JNJ-872 is an inhibitor of influenza virus replication that offers a potential for the treatment of pandemic and seasonal influenza.

LASCUFLOXACIN, a fluoroquinolone derivative, is an antibacterial agent with a broad spectrum of activity against various clinical isolates. It is under development for the treatment of respiratory tract infections and community-acquired pneumonia.

Delmetacin is a non-steroidal anti-inflammatory agent related to indomethacin. It has analgesic, antipyretic and anti-inflammatory properties.

LASINAVIR, a hydroxyethylene derivative, is highly specific human immunodeficiency virus (HIV) protease inhibitor with an IC50 of 1 nM. Its clinical development was discontinued.

Mipitroban (previously known as UP 11677), a thromboxane A2 receptor antagonist that was investigated to treat thrombosis. However, further studies were apparently discontinued.